To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. Chief Executive Officers, Heads of Cultivation, Directors of Extraction Operations, Quality Assurance Managers, Regulatory Affairs Specialists, and Product Development were among the supply-side suppliers. leads from multi-state operators, authorized medical cannabis producers, and processors. Procurement officers from hospital pharmacies, specialty cannabis dispensaries, and alternative treatment facilities were among the demand-side sources, along with neurologists, oncologists, psychiatrists, clinical pharmacists, medical directors of medical cannabis clinics, and pain management specialists. In addition to verifying clinical trial pipelines and validating market segmentation across therapeutic applications, primary research also collected data on patient enrollment trends, dosing guidelines, reimbursement status, and product formulation preferences.
Primary Respondent Breakdown:
• By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
• By Region: North America (40%), Europe (25%), Asia-Pacific (22%), Rest of World (13%)
Global market valuation was derived through licensed producer revenue mapping and patient volume analysis. The methodology included:
• Identification of 50+ licensed cultivators and processors across North America, Europe, Asia-Pacific, and Latin America
• Product mapping across flower/bud, oils/extracts, tinctures, infused edibles, topicals, and synthetic cannabinoid formulations
• Analysis of reported and modeled annual revenues specific to medical cannabis portfolios (excluding recreational/adult-use sales where legally separable)
• Coverage of licensed producers representing 65-70% of total legal medical cannabis market share in 2024
• Extrapolation using bottom-up (registered patient counts × average monthly consumption × average selling price by jurisdiction) and top-down (licensed producer revenue validation) approaches to derive segment-specific valuations for pain management, neurological disorder treatment, oncology applications, and mental health therapies